Zhengquan Chu - Search Results

Year	Number of Results
2018	1
2019	3
2020	4
2021	9
2022	6
2023	11
2024	7

1

Glioma targeted therapy: insight into future of molecular approaches.

Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Zhang X, Zhang L, Peng Y, Ye W, Zeng W, Liu Z, Cheng Q. Yang K, et al. Mol Cancer. 2022 Feb 8;21(1):39. doi: 10.1186/s12943-022-01513-z. Mol Cancer. 2022. PMID: 35135556 Free PMC article. Review.

2

Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials.

Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N, Liu Z, Yang L, Jiang Q, Cheng Q, Luo P, Liu G. Zhang H, et al. Mol Cancer. 2023 Oct 2;22(1):159. doi: 10.1186/s12943-023-01860-5. Mol Cancer. 2023. PMID: 37784082 Free PMC article. Review.

3

Tumor buster - where will the CAR-T cell therapy 'missile' go?

Qu C, Zhang H, Cao H, Tang L, Mo H, Liu F, Zhang L, Yi Z, Long L, Yan L, Wang Z, Zhang N, Luo P, Zhang J, Liu Z, Ye W, Liu Z, Cheng Q. Qu C, et al. Mol Cancer. 2022 Oct 19;21(1):201. doi: 10.1186/s12943-022-01669-8. Mol Cancer. 2022. PMID: 36261831 Free PMC article. Review.

4

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.

Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, Zeng WJ, Liu Z, Cheng Q. Zhang H, et al. J Exp Clin Cancer Res. 2021 Jun 4;40(1):184. doi: 10.1186/s13046-021-01987-7. J Exp Clin Cancer Res. 2021. PMID: 34088360 Free PMC article. Review.

5

The pentraxin family in autoimmune disease.

Li Y, Zhang S, Liu J, Zhang Y, Zhang N, Cheng Q, Zhang H, Wu X. Li Y, et al. Clin Chim Acta. 2023 Nov 1;551:117592. doi: 10.1016/j.cca.2023.117592. Epub 2023 Oct 11. Clin Chim Acta. 2023. PMID: 37832905 Review.

6

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.

Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, Zhang L, Hu J, Luo P, Zhang J, Liu Z, Peng Y, Liu Z, Tang L, Cheng Q. Wang Y, et al. J Hematol Oncol. 2022 Aug 17;15(1):111. doi: 10.1186/s13045-022-01325-0. J Hematol Oncol. 2022. PMID: 35978433 Free PMC article. Review.

7

Exosome-based nanoimmunotherapy targeting TAMs, a promising strategy for glioma.

Luo H, Zhang H, Mao J, Cao H, Tao Y, Zhao G, Zhang Z, Zhang N, Liu Z, Zhang J, Luo P, Xia Y, Cheng Y, Xie Z, Cheng Q, Liu G. Luo H, et al. Cell Death Dis. 2023 Apr 3;14(4):235. doi: 10.1038/s41419-023-05753-9. Cell Death Dis. 2023. PMID: 37012233 Free PMC article. Review.

8

LINC00978 regulates metabolic rewiring to promote the malignancy of glioblastoma through AKR1B1.

Meng M, Yang L, Zhou H, Cheng Q, Peng R, Wang Z, Liang X, Wen J, Nie J, Hu Z, Zhang L, Liu Z. Meng M, et al. Cancer Lett. 2023 Jul 28;567:216277. doi: 10.1016/j.canlet.2023.216277. Epub 2023 Jun 17. Cancer Lett. 2023. PMID: 37336288 Free article.

9

Oxidative stress is involved in immunosuppression and macrophage regulation in glioblastoma.

Liang X, Wang Z, Dai Z, Liu J, Zhang H, Wen J, Zhang N, Zhang J, Luo P, Liu Z, Liu Z, Cheng Q. Liang X, et al. Clin Immunol. 2024 Jan;258:109802. doi: 10.1016/j.clim.2023.109802. Epub 2023 Oct 20. Clin Immunol. 2024. PMID: 37866784

10

Identification of a single cell-based signature for predicting prognosis risk and immunotherapy response in patients with glioblastoma.

Dai Z, Zhang N, Zhou R, Zhang H, Zhang L, Wang Z, Zeng W, Luo P, Zhang J, Liu Z, Cheng Q. Dai Z, et al. Clin Immunol. 2023 Jun;251:109345. doi: 10.1016/j.clim.2023.109345. Epub 2023 Apr 24. Clin Immunol. 2023. PMID: 37100336

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

35 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year